KRAS and non-small cell lung carcinoma: In conclusion, our study provides valuable insights into the interplay between PD-L1 expression, HIF-1α expression, and KRAS mutation status in non-small cell lung cancer (NSCLC), particularly in KRAS G12C mutant cases.